Skip to main content

Lupus

      RT @DrCassySims: 🔥Ignite Talk 10:20AM South Philly Stage🔥 abstract #0946

      SLE, birth control, & pregnancy pla
      1 year 11 months ago
      🔥Ignite Talk 10:20AM South Philly Stage🔥 abstract #0946 SLE, birth control, & pregnancy planning 🔥30% of women used no birth control despite only 17% voicing interest in pregnancy 🔥More 1/2 of women interested in pregnancy were not medically ready #ACR22 @RheumNow
      RT @RichardPAConway: Kahlenberg @Kahlenberglab et al. TYK2i deucravacitinib in SLE. Clinical efficacy (figure). Deucrava
      1 year 11 months ago
      Kahlenberg @Kahlenberglab et al. TYK2i deucravacitinib in SLE. Clinical efficacy (figure). Deucravacitinib suppressed IFN production, IFN-responsive gene expression, IFN-inducible proteins, B cell markers,serological biomarkers. @RheumNow #ACR22 Abstr#1000 https://t.co/zzkoPLOlSR https://t.co/znyG8N5pJ2
      RT @uptoTate: Severe non-adherence to HCQ independently assoc'd w/ risk of SLE flare in the following year, with early d
      1 year 11 months ago
      Severe non-adherence to HCQ independently assoc'd w/ risk of SLE flare in the following year, with early damage, and 5-year mortality. Abs 0343 #ACR22 @RheumNow https://t.co/JYRWD5QIlf https://t.co/UCWYrHIc4b
      RT @RichardPAConway: Gopal et al. Withdrawal of immunosuppressants non-inferior to steroid withdrawal in SLE in clinical
      1 year 11 months ago
      Gopal et al. Withdrawal of immunosuppressants non-inferior to steroid withdrawal in SLE in clinical remission. Numerically higher flare rate in steroid withdrawal group 15 vs 7 (RR 2.1). @RheumNow #ACR22 Abstr#0997 https://t.co/psoHvg0pVG https://t.co/GlsDjpgXGo
      Once in a while, I find an abstract at the American College of Rheumatology meeting that can potentially save lives and be implemented in practice now.   In Abstract #0939, Dr. J Patricia…
      New Treatments for SLE?
      RT @ericdeinmd: Ab0676 #ACR22 Adrenal hemorrhage in APLS
      59 pts from SLE cohort + 181 from lit review
      65% prior VTE, 12%
      1 year 11 months ago
      Ab0676 #ACR22 Adrenal hemorrhage in APLS 59 pts from SLE cohort + 181 from lit review 65% prior VTE, 12% CVA, 24% OB morbidity 46% thrombocyt, 21% had SLE 58% on a/c 69% b/l hemorrhage 63% adrenal insuff Radiol remission: 6% at 1 yr, 41% at 5yr Death 2% 1 yr, 11% at 5 @RheumNow https://t.co/EacifcN7Sd
      RT @ericdeinmd: Ab0683 #ACR22
      aPL Pts ANA pos vs neg:
      521 pts with +aPL Ab WO other autoimmune disease
      224 +ANA, 297 -A
      1 year 11 months ago
      Ab0683 #ACR22 aPL Pts ANA pos vs neg: 521 pts with +aPL Ab WO other autoimmune disease 224 +ANA, 297 -ANA ANA+ ass w/ hemolytic anemia, thrombocyt, leukopenia, livedo, unexplained fetal death Trend for arthritis, aPL nephropathy @RheumNow https://t.co/3NHGymyL1C
      RT @ericdeinmd: Ab0674 #ACR22 HIT AND APLS??
      Retrosp review of 23 pts treated for HIT in the hospital with APLS or SLE w
      1 year 11 months ago
      Ab0674 #ACR22 HIT AND APLS?? Retrosp review of 23 pts treated for HIT in the hospital with APLS or SLE with aPL Ab: Not one ultimately met clinical criteria for HIT 1 pt had PF4 antibodies, SRA testing negative in ALL cases Thrombocytopenia w/ aPL Abs? Think APS 1st! @Rheumnow https://t.co/ZYZP5VZF0R